Fundamental Analysis of Halozyme Therapeutics Inc - Growth / Value Index
HALO - Valuation Highlights
Valuation Analysis
Tsr Value Index - Good Score of 67.19
Undervalued - Price to Intrinsic Value of 0.133
Price to Book Ratio of 39.95 suggesting that it is very expensive
Book Value in last 3 years is trending down
Valuation Key Ratios
| Ratio | TTM | Latest FY | Yoy Change | MRQ |
|---|---|---|---|---|
| Price to Earning | 18.61 | 21.31 | -34.33 % | |
| Price to Book | 40.76 | 71.59 | 85.35 % | 32.41 |
| Price to Sales | 6.87 | 7.24 | -27.18 % | |
| Enterprise Value to EBITDA Multiple | 17.76 | 17.55 | -29.29 % |
HALO - Profitability Highlights
Profitability Analysis
Piotroski F Score - Good Value of 7.0
Excellent Net Margin for last 3 years
Company Earning excess return
During the past twelve months, the company has given a strong Return On Equity of 219.05%
During the past twelve months, the company has given a strong Net Margin of 36.94%
All key Trailing Twelve Months Margin growing by 15 %
Reasonable Dividend Yield of 3.06 %
EBITDA is continuously increasing for last 3 Years
Good Return On Capital Employed of 17.79
Low Earning Yield of 5.48 %
Profitability Key Ratios
| Ratio | TTM | Latest FY | Yoy Change | MRQ |
|---|---|---|---|---|
| Return On Equity | 219.05 | 336.00 | 182.26 % | 43.21 |
| Return On Asset | 17.76 | 16.25 | 48.01 % | 4.17 |
| Net Profit Margin | 36.94 | 33.96 | 10.90 % | 39.22 |
| Operating Profit Margin | 43.95 | 40.71 | 0.445 % | 48.78 |
| EBITDA Margin | 46.35 | 50.94 | 6.58 % | 48.78 |
Highlights
| Market Cap | 5690.42 M |
| Enterprise Value | 7103.50 M |
| Price/Book TTM | 40.76 |
| Outstanding Share | 127274 K |
| Float/ Outstanding Share | 98.91% |
| Dividend Yield | 3.06 % |
Share Holding
Guru Numbers
| Price/Graham No | 7.69 |
| Peter Lynch Ratio | 2.81 |
| Piotroski F Score | 7.00 |
| Altman Z Score | 3.70 |
| Sloan Ratio | -0.062 |
| Peter Lynch Fair Value | 60.07 |
HALO - Growth Highlights
Growth Analysis
Tremendous increasing trend in total sale last 3 year
Growth Key Fields
| Field | TTM | YoY Growth | QoQ Growth |
|---|---|---|---|
| Revenue | 862989 K | 25.62 % | 14.85 % |
| Gross Profit | 677469 K | 22.29 % | 5.73 % |
| EBITDA | 400007 K | 33.89 % | 21.51 % |
| Net Profit | 318802 K | 39.31 % | 10.03 % |
| EPS | 2.40 | 52.28 % | NA |
HALO - Stability Highlights
Stability Analysis
Altman Z Score of 3.66 suggests good Stability
Tsr Stability Index - Very Poor Score of 15.62
Company has high debt burden
Stability Key Ratios
| Ratio | Latest FY | Yoy Change | MRQ |
|---|---|---|---|
| Debt to Equity Ratio | 18.27 | 106.01 % | 8.62 |
| Cash Ratio | 2.99 | 7.68 % | |
| Quick Ratio | 5.50 | 12.61 % | 5.36 |
| Shareholders Equity | 4.84 | -47.56 % | |
| Debt to EBITDA | 3.63 | -24.05 % |
Historical Valuation Ratios of Halozyme Therapeutics Inc
Historical Valuation Ratios
Loading ...
Historical Profitability Ratios of Halozyme Therapeutics Inc
Historical Profitability Ratios
Loading ...
Historical Efficiency Ratios of Halozyme Therapeutics Inc
Historical Efficiency Ratios
Loading ...
Historical Solvency Ratios of Halozyme Therapeutics Inc
Historical Solvency Ratios
Loading ...
Note : All Data Generated at the End of Trading Hours (EOD Data)